The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Jounce Therapeutics, Inc

9 Mar 2023 11:22

RNS Number : 4654S
Redx Pharma plc
09 March 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Jounce Therapeutics, Inc ("Jounce")

(d) Is the discloser the offeror or the offeree?

Offeree

(e) Date position held:

The latest practicable date prior to the disclosure

9 March 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes - Redx Pharma plc

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Jounce common shares of $0.001 par value per share ("Shares")

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

-

0

-

(2) Cash-settled derivatives:

 

0

-

0

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

-

0

-

TOTAL:

0

-

0

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Registered holder

Class

Number of Shares

Percentage shareholding (%)

Sidley Austin Master Pension Trust ("SAMP Trust")

Jounce common shares of $0.001 par value per share

2,968

0.00569234%

SA Investment Partnership IV LLC ("SAIP IV")

Jounce common shares of $0.001 par value per share

1,978

0.00379361%

 

The SAMP Trust is a benefit plan trust that holds certain assets of Sidley Austin LLP's U.S.-based retirement plans. SAIP IV is an employees' securities company whose members are current or former partners or senior staff members of Sidley Austin LLP (or trusts formed by such persons).

 

Sidley Austin LLP is acting as legal adviser to RedCo II Master Fund, L.P. and RM Special Holdings 3, LLC.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

9 March 2023

Contact name:

Claire Solk, Group Company Secretary

Telephone number:

+44(0)1625 469900

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEFLFFLVIIAIIV
Date   Source Headline
5th Aug 20207:00 amRNSAppointment of NED and changes to Board committees
4th Aug 20207:37 amRNSOut licensing agreement with AstraZeneca
20th Jul 202011:35 amRNSResult of General Meeting
2nd Jul 20202:05 pmRNSSecond Price Monitoring Extn
2nd Jul 20202:00 pmRNSPrice Monitoring Extension
1st Jul 202012:30 pmRNSDirector/PDMR Shareholding
30th Jun 202011:30 amRNSHolding(s) in Company
30th Jun 20207:46 amRNSShare Option Scheme
30th Jun 20207:02 amRNSInterim Results
30th Jun 20207:00 amRNSProposed financing of $30m and notice of GM
15th Jun 202011:05 amRNSSecond Price Monitoring Extn
15th Jun 202011:00 amRNSPrice Monitoring Extension
20th May 20207:00 amRNSChange of Adviser
18th May 20207:00 amRNSAppointment of Non-Executive Director
6th May 20208:45 amRNSHolding(s) in Company
5th May 20209:45 amRNSHolding(s) in Company
4th May 20209:32 amRNSForm 8.3 - [REDX PHARMA PLC]
1st May 202011:45 amRNSForm 8.5 (EPT/RI)
1st May 20207:00 amRNSOffer Closed
29th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Apr 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Apr 202011:32 amRNSResult of AGM and operational update
21st Apr 202011:45 amRNSForm 8.5 (EPT/RI)
20th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
17th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
15th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
14th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
9th Apr 20206:10 pmRNSRedx Pharma
9th Apr 20204:47 pmRNSPUBLICATION OF OFFER DOCUMENT
9th Apr 20201:58 pmRNSOffer Update - Share Acquisitions
7th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
6th Apr 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Apr 20209:44 amRNSForm 8 (DD) - Redx Pharma PLC
3rd Apr 20209:27 amRNSForm 8.5 - RedX Pharma Plc
3rd Apr 20209:14 amRNSHolding(s) in Company
3rd Apr 20207:00 amRNSForm 8.3 - Redx Pharma plc
2nd Apr 20202:31 pmRNSOffer Update - Share Acquisitions
2nd Apr 202012:27 pmRNSForm 8.5 - RedX Pharma Plc
2nd Apr 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Apr 202011:20 amRNSHolding(s) in Company
2nd Apr 20209:55 amRNSForm 8 (DD) - Redx Pharma PLC
1st Apr 202012:13 pmRNSForm 8.5 - Redx Pharma Plc
1st Apr 202011:01 amRNSForm 8 (DD) - Redx Pharma PLC
31st Mar 20207:00 amRNSInformation regarding Company AGM
30th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
30th Mar 20207:00 amRNS£5 million short term loan agreement
27th Mar 202011:45 amRNSForm 8.5 (EPT/RI)
27th Mar 202011:43 amRNSForm 8 (OPD) - Redx Pharma Plc
26th Mar 20202:03 pmRNSForm 8.3 - Redx Pharma plc
26th Mar 20201:42 pmRNSForm 8.3 - Redx Pharma plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.